Literature DB >> 23591597

miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells.

Chen Zhu1, Jie Li, Gong Cheng, Hai Zhou, Liangjun Tao, Hongzhou Cai, Pu Li, Qiang Cao, Xiaobing Ju, Xiaoxin Meng, Meilin Wang, Zhengdong Zhang, Chao Qin, Lixin Hua, Changjun Yin, Pengfei Shao.   

Abstract

Epithelial-mesenchymal transition (EMT) is a crucial process that plays an important role in the invasion and metastasis of human cancers. High-mobility group AT-hook 2 (HMGA2) has been found to be involved in the EMT program, with its aberrant expression having been observed in a variety of malignant tumors. However, the mechanisms regulating HMGA2 expression remain incompletely understood. The objective of this study was to investigate whether mir-154 plays a critical role in EMT by regulating HMGA2. The expression levels of HMGA2 were examined in four samples of prostate cancer (PCa) tissue and adjacent non-tumorous tissue by Western blot analysis. The effects of forced expression of miR-154 or HMGA2 knockdown on PCa cells were evaluated by cell migration and invasion assays and Western blot analysis. HMGA2 was upregulated in the PCa tissue samples compared with the adjacent normal ones. Forced expression of miR-154 or HMGA2 knockdown significantly reduced the migratory and invasive capabilities of PCa cells in vitro and inhibited EMT gene expression, increased the levels of E-cadherin, an epithelial marker, and decreased the levels of vimentin, a mesenchymal marker. HMGA2 is a direct target gene of miR-154 by dual-luciferase reporter assay. Our findings suggest that miR-154 plays a role in regulating EMT by targeting HMGA2. Understanding the targets and regulating pathways of miR-154 may provide new insights into the underlying pathogenesis of PCa.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23591597     DOI: 10.1007/s11010-013-1628-4

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  25 in total

1.  Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis HMGA2 as a prognostic marker of bladder cancer.

Authors:  G L Yang; L H Zhang; J J Bo; K L Hou; X Cai; Y Y Chen; H Li; D M Liu; Y R Huang
Journal:  Eur J Surg Oncol       Date:  2011-01-26       Impact factor: 4.424

2.  HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors.

Authors:  P Rogalla; K Drechsler; G Frey; Y Hennig; B Helmke; U Bonk; J Bullerdiek
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

3.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene.

Authors:  Yong Sun Lee; Anindya Dutta
Journal:  Genes Dev       Date:  2007-04-16       Impact factor: 11.361

4.  Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation.

Authors:  Christine Mayr; Michael T Hemann; David P Bartel
Journal:  Science       Date:  2007-02-22       Impact factor: 47.728

5.  HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer.

Authors:  Gerhild Fabjani; Dan Tong; Andrea Wolf; Sebastian Roka; Sepp Leodolter; Paul Hoecker; Michael Bernhard Fischer; Raimund Jakesz; Robert Zeillinger
Journal:  Oncol Rep       Date:  2005-09       Impact factor: 3.906

6.  HMGA2 overexpression in non-small cell lung cancer.

Authors:  Britta Meyer; Siegfried Loeschke; Anke Schultze; Thomas Weigel; Martin Sandkamp; Torsten Goldmann; Ekkehard Vollmer; Jörn Bullerdiek
Journal:  Mol Carcinog       Date:  2007-07       Impact factor: 4.784

7.  HMGA2 expression in a canine model of prostate cancer.

Authors:  Susanne Winkler; Hugo Murua Escobar; Britta Meyer; Daniela Simon; Nina Eberle; Wolfgang Baumgartner; Siegfried Loeschke; Ingo Nolte; Jörn Bullerdiek
Journal:  Cancer Genet Cytogenet       Date:  2007-09

Review 8.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma.

Authors:  Carla Hebert; Kathleen Norris; Mark A Scheper; Nikolaos Nikitakis; John J Sauk
Journal:  Mol Cancer       Date:  2007-01-14       Impact factor: 27.401

View more
  38 in total

1.  microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma.

Authors:  Shweta Dambal; Angeline A Giangreco; Andres M Acosta; Andrew Fairchild; Zachary Richards; Ryan Deaton; Dennis Wagner; Reinhold Vieth; Peter H Gann; Andre Kajdacsy-Balla; Theodorus Van der Kwast; Larisa Nonn
Journal:  J Steroid Biochem Mol Biol       Date:  2017-01-12       Impact factor: 4.292

2.  Silencing of HMGA2 promotes apoptosis and inhibits migration and invasion of prostate cancer cells.

Authors:  Zhan Shi; Ding Wu; Run Tang; Xiang Li; Renfu Chen; Song Xue; Chengjing Zhang; Xiaoqing Sun
Journal:  J Biosci       Date:  2016-06       Impact factor: 1.826

3.  Aberrant ceRNA activity drives lung cancer.

Authors:  Yvonne Tay; Florian A Karreth; Pier Paolo Pandolfi
Journal:  Cell Res       Date:  2014-02-14       Impact factor: 25.617

4.  IL-8 induces the epithelial-mesenchymal transition of renal cell carcinoma cells through the activation of AKT signaling.

Authors:  Nan Zhou; Fuding Lu; Cheng Liu; Kewei Xu; Jian Huang; Dexin Yu; Liangkuan Bi
Journal:  Oncol Lett       Date:  2016-07-21       Impact factor: 2.967

5.  MicroRNA-154/ADAM9 axis inhibits the proliferation, migration and invasion of breast cancer cells.

Authors:  Chengwei Qin; Yanming Zhao; Chunzhi Gong; Zhenlin Yang
Journal:  Oncol Lett       Date:  2017-09-21       Impact factor: 2.967

6.  Solamargine inhibits the migration and invasion of HepG2 cells by blocking epithelial-to-mesenchymal transition.

Authors:  Xiaodong Xie; Haitao Zhu; Jia Zhang; Meiqin Wang; Li Zhu; Zhen Guo; Wenrong Shen; Dongqing Wang
Journal:  Oncol Lett       Date:  2017-05-10       Impact factor: 2.967

7.  MiR-154 Functions as a Tumor Suppressor in Glioblastoma by Targeting Wnt5a.

Authors:  Dongsheng Zhao; Rencong Wang; Junkang Fang; Xituan Ji; Juan Li; Xiaoyan Chen; Gangfeng Sun; Zhengjun Wang; Weiping Liu; Yangang Wang; Guang Cheng; Haining Zhen; Chunhua Sun; Zhou Fei
Journal:  Mol Neurobiol       Date:  2016-03-25       Impact factor: 5.590

8.  Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells.

Authors:  Chen Qu; Weijia Zhang; Guopei Zheng; Zijuan Zhang; Jiang Yin; Zhimin He
Journal:  Mol Cell Biochem       Date:  2013-10-06       Impact factor: 3.396

9.  Novel Association of miR-451 with the Incidence of TEVG Stenosis in a Murine Model.

Authors:  Narutoshi Hibino; Cameron A Best; Alyson Engle; Svetlana Ghimbovschi; Susan Knoblach; Dilip S Nath; Nobuyuki Ishibashi; Richard A Jonas
Journal:  Tissue Eng Part A       Date:  2015-12-17       Impact factor: 3.845

10.  miR-154 inhibits migration and invasion of human non-small cell lung cancer by targeting ZEB2.

Authors:  Xingyu Lin; Zhiguang Yang; Peng Zhang; Yunpeng Liu; Guoguang Shao
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.